Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms- |
Target |
Action degraders |
Mechanism MEK1 degraders(Dual specificity mitogen-activated protein kinase kinase 1 degraders), MEK2 degraders(Dual specificity mitogen-activated protein kinase kinase 2 degraders), Proteolysis |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC77H94F3IN18O12S |
InChIKeyXPXBOJCDLYUMCO-WXWGOGOJSA-N |
CAS Registry2769735-56-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 25 Mar 2022 |